🇺🇸 recombinant human endostatin in United States

10 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Adrenal Insufficiency — 1 report (10%)
  2. Anaemia — 1 report (10%)
  3. Arthralgia — 1 report (10%)
  4. Asthenia — 1 report (10%)
  5. Blood Albumin Decreased — 1 report (10%)
  6. Bone Marrow Failure — 1 report (10%)
  7. Cardiotoxicity — 1 report (10%)
  8. Chest Discomfort — 1 report (10%)
  9. Cough — 1 report (10%)
  10. Decreased Appetite — 1 report (10%)

Source database →

Other Oncology approved in United States

Frequently asked questions

Is recombinant human endostatin approved in United States?

recombinant human endostatin does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for recombinant human endostatin in United States?

Peking University Cancer Hospital & Institute is the originator. The local marketing authorisation holder may differ — check the official source linked above.